Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 11/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110384 | 0.85 | PSEN1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1110361 | 0.83 | MMP12 (0.32) | ITGA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1110582 | 0.82 | KEAP1 (0.41) | TRPM8 | |
| SCHEMBL1110202 | 0.81 | MMP12 (0.37) | BDKRB1PPARATP53ACLY | |
| SCHEMBL1321251 | 0.80 | MMP12 (0.36) | BDKRB1MAPT | |
| SCHEMBL1318290 | 0.80 | PSEN1 (0.35) | ITGA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1110486 | 0.80 | MMP12 (0.35) | BDKRB1MAPT | |
| SCHEMBL1110375 | 0.78 | MMP13 (0.39) | ITGA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2055497 | 0.78 | TRPM8 (0.33) | ITGA4TRPM8BDKRB1MAPTTP53 | |
| SCHEMBL12116144 | 0.76 | NR1D1 (0.35) | ITGA4TRPM8BDKRB1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2279173-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | ITGA4 3203/4885TRPM8 4510/4885PSEN1 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.